Skip to main content
. 2019 Nov 21;63(12):e01201-19. doi: 10.1128/AAC.01201-19

FIG 3.

FIG 3

Antiviral activity. (A) Mean (+SD) HCV RNA change from baseline with ascending doses (6 subjects per dose) in noncirrhotic (NC) GT1b subjects and with 600 mg QD in NC GT1b (n = 6), NC GT3 (n = 6), and cirrhotic (GT1, -2, or -3; n = 6) subjects. (B) HCV RNA changes from baseline in individual subjects receiving 600 mg QD.